FGEN

FibroGen, Inc

1.13 USD
0.00 (0.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

FibroGen, Inc stock is down -11.72% since 30 days ago. The next earnings date is Aug 5, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 70% of the previous 9 June’s closed higher than May. In the last 3 Unusual Options Trades, there were 3 CALLs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
07 May 15:51 20 Sep, 2024 5.00 CALL 1077 1015
28 May 15:33 19 Jul, 2024 2.50 CALL 852 10772
21 Jun 15:15 20 Sep, 2024 2.50 CALL 1234 1174

About FibroGen, Inc

FibroGen, Inc. discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan. Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor, is in Phase III.